Romidepsin (FK228, Depsipeptide)

目录号:S3020 别名: FR 901228, NSC 630176

Romidepsin (FK228, Depsipeptide) Chemical Structure

Molecular Weight(MW): 540.7

Romidepsin (FK228, Depsipeptide)是一种有效的HDAC1HDAC2抑制剂,无细胞试验中IC50分别为36 nM和47 nM。

规格 价格 库存 购买数量  
RMB 1285.83 现货
RMB 3910.79 现货
RMB 5710.89 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献20篇:

客户使用该产品的6个实验数据:

  • Concentration over time for each dose cohort of romidepsin (B).

    Blood, 2018, 131(4):397-407. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    PBMCs from a patient were incubated with diverse agents (2 μM Compound E, 2 nM Bortezomib and 1nM Romidepsin) for 48 hours. Apoptosis detection was performed by Annexin V/PI staining and analyzed by flow cytometry. Annexin V+/PI− (lower right quadrant) areas stand for early apoptotic cells, and Annexin V+/PI+ (upper right quadrant) areas stand for late apoptotic or necrotic cells.

    Leukemia, 2015, 29(3):556-66. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

  • Effects of combination of bort/romidepsin on HDAC6 inhibition and activation of ER stress signaling. HA cells were treated with combination of 15 nM bortezomib and 5 nM romidepsin or either drug alone for 24 hr. Expression of CHOP/GADD153 (green signals) and cleaved PARP (red signals) was detected by immunofluorescent staining. DAPI (blue signals) stained the cell nuclei.

    Int J Cancer 2014 135(12):2950-61. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    An HIV-Gag-SLYNTVATL-specific CTL clone was labeled with Alexa-Fluor555 conjugated cholera toxin subunit B either cultured with 500 nM SAHA or 25 nM romidepsin for 20 hours, or maintained as an untreated control. These effector cells were combined with SLYNTVATL peptide pulsed target cells, matched on the restricting allele, in a collagen matrix medium containing sytox green viability dye. These mixtures were then plated in three separate wells of an 8-well cover slip and imaged by time-lapse brightfield and fluorescent microscopy. A. Shown are representative fields of view from the no treatment (upper panel), 500 nM SAHA (middle panel), and 25 nM romidepsin (lower panel) conditions advancing in time from left to right. Time stamps are given in hh[ratio]mm format. Clones described in the results are indicated with yellow arrows and killed target cells are indicated with white arrows in the upper right panel.

    PLoS Pathog 2014 10(8), e1004287. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

  • PLZF-RARa–nonexpressing and -expressing PLZFRARβ3 cells were treated with 5 nmol/L romidepsin for the indicated time points. Induction of the DNA DSB marker γH2AX was measured by Western blotting. β-Actin was used as a loading control.

    Mol Cancer Ther 2013 12(8), 1591-604. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    Impacts of chromopeptide A and FK228 on G2/M transition regulators. PC3 and LNCaP cells were treated with chromopeptide A or FK228 at indicated concentrations for 24 h, and cells lysates were immunoblotted with the indicated antibodies.

    Acta Pharmacol Sin, 2017, 38(4):551-560. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述 Romidepsin (FK228, Depsipeptide)是一种有效的HDAC1HDAC2抑制剂,无细胞试验中IC50分别为36 nM和47 nM。
特性 Romidepsin对I型HDAC的抑制作用明显强于对II型HDAC的抑制。
靶点
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
36 nM 47 nM
体外研究

Romidepsin抑制NSCLC细胞系生长,IC50范围从1.3 ng/mL到4.9 ng/mL。 Romidepsin可以降低Erlotinib对NSCLC细胞系的IC50值, 增加NSCLC细胞系对Erlotinib的敏感性[1]。Romidepsin处理72小时可以抑制6/6 人 NB 肿瘤细胞系的生长,而 NIH3T3细胞系并不受影响。 Romidepsin对于单拷贝或N-myc 多拷贝的NB细胞系以及含有正常或突变的p53 和含有Alk突变体的细胞系都有选择性的细胞毒性,这种毒性具有剂量依赖的特性。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SU-DHL4 NU\WWXA1S2WubDDWbYFjcWyrdImgRZN{[Xl? NFTMZpYzNjVvMUWgcm0> M{LFO|czKGh? NUHjZ21McW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= M3fqcVI2PzlyOUC3
U2932  NGPoTJlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MmT5Nk42NTF3IH7N MlXRO|IhcA>? MV\pcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh M3P3ZlI2PzlyOUC3
OCI-LY7 NFLpW5dE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MX:yMlUuOTVibl2= MVm3NkBp NUjue3E4cW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= MlnnNlU4QTB7MEe=
Farage NEniNGhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NXTSR4tTOi53LUG1JI5O NWjZR4l{PzJiaB?= NGTJUnNqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi M2X0UlI2PzlyOUC3
LY7/EBV NVLCPHY2S2WubDDWbYFjcWyrdImgRZN{[Xl? NFTWUpYzNjVvMUWgcm0> NHjjO2M4OiCq M13oTYlv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? NIXPc|gzPTd7MEmwOy=>
U2932/EBV M1G3TWNmdGxiVnnhZoltcXS7IFHzd4F6 M2XpblIvPS1zNTDuUS=> MYS3NkBp M2LhWolv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? MojoNlU4QTB7MEe=
HCT116 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fxcFUuPTByMDDuUS=> NHz5[HczPCCq MVfEUXNQ MWnpcoR2[2W|IHPlcIwh\GWjdHigbY4h[SClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYK= NWnW[3RmOjV2OUK1NVU>
ACH-2 MVLGeY5kfGmxbjDBd5NigQ>? MVWxMVkhdk1? MVSyOEBp NF7vZY1qdmS3Y3XzJGhKXi1zIFXuekBmgHC{ZYPzbY9v NHO1ZpkzPTF2OUS2Oy=>
MCF-10A MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTBwMUhCtVAvODFibl2= MonNNlQ6PTR6NU[=
MCF-7 NI[4[W1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvkTWM2OD1zLkGwxtExNjJyIH7N NYHH[nc6OjR7NUS4OVY>
SK-BR-3 Mlu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTNTWM2OD1zLkCwxtExNjN3IH7N M4LhUVI1QTV2OEW2
MDA-MB-231 NUSxdJZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rCdmlEPTB;MD62POKyOC5zNDDuUS=> M3j4dVI1QTV2OEW2
PC3 NVPBWHhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nqNWlEPTB;MT62OeKyOC5|NTDuUS=> MXGyOFk2PDh3Nh?=
HCT116 NI\FSnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HiXmlEPTB;MT6wNOKyOC5yMDDuUS=> MmHuNlQ6PTR6NU[=
HCT116-p21-/- M{GyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTNTWM2OD1zLkK2xtExNjN5IH7N NFHlZ|MzPDl3NEi1Oi=>
S1 NX[1bHAyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTdwNkhCtVAvOjlibl2= M2\FVFI1QTV2OEW2
SW620 NVP6OZdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknOTWM2OD1yLkmzxtExNjJ7IH7N NYLZdlZwOjR7NUS4OVY>
LOX-IMVI Mm\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwOEhCtVAvODNibl2= NX72[45VOjR7NUS4OVY>
UACC-62 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjqeJRKSzVyPUCuOVbDuTBwMU[gcm0> MU[yOFk2PDh3Nh?=
MDA-MB-435 M2HLPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkO5TWM2OD1yLkmwxtExNjB4IH7N NIrYOoQzPDl3NEi1Oi=>
SF-295 NXm0N2o1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NID6WohKSzVyPUCuPFjDuTBwMUWgcm0> MlHvNlQ6PTR6NU[=
A549 M{LEVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fhUGlEPTB;MT6yOuKyOC5{NDDuUS=> M334[|I1QTV2OEW2
H460 M2HVSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nuV2lEPTB;Mj61POKyOC56MDDuUS=> NELDXHIzPDl3NEi1Oi=>
EKVX MmDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGe5XoZKSzVyPUGuN|PDuTBwM{Sgcm0> MkS2NlQ6PTR6NU[=
H146 MofSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHP0bGdKSzVyPUCuNlLDuTBwMEegcm0> Mm\oNlQ6PTR6NU[=
H526 M3HBdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIGzSGVKSzVyPUCuNVXDuTBwMEOgcm0> NFrFfVMzPDl3NEi1Oi=>
HuT-78 MnHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIP5fW9KSzVyPUGuO|PDuTBwNESgcm0> Ml\tNlQ6PTR6NU[=
HA NUTWeGNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUCwMlYzPS1zMH7N MlHXOFghcA>? NYjXU45McW6mdXPld{BiKHOrZ37p[olk[W62bImgd5Rzd26pZYKgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iY3:teJJm[XSnZDD3bZRpKGKxcoTlfo9ucWJ? MmrNNlQ4PzF3MUC=
MS-275 NV7mbVhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrKOY8xNjZ{NT2xNI5O NHTnNJA1QCCq NYrO[llucW6mdXPld{BiKHOrZ37p[olk[W62bImgd5Rzd26pZYKgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iY3:teJJm[XSnZDD3bZRpKGKxcoTlfo9ucWJ? MV[yOFc4OTVzMB?=
CD4 T NVX6TJVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYG0PEBp M2D4R2VEPTB;ND61xtEyNjBibl2= NFjhR3czPDd{MkS1OC=>
CD4 T NF3WWXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHnRlhkPDhiaB?= MUXDR|UxRTFyN9MxNVI3KG6P NWjw[VhrOjR5MkK0OVQ>
CD4+ T NFLRbYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rybWVEPTB;MzDuUS=> M{O1elI1PDl3MUC1
A549 NYnZeZl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrzdoJnOTEkgKOxNFDDqG6P MkfNNlQwOzZxNEigbC=> M4j1WYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIgh[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NYPYemh{OjR2OEW3PVk>
JJN3 Ml;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkO5NlQwPDhiaB?= Ml3tSWM2ODxz4pEJcm08KDR64pEJbC=> NIr4S5EzPDB|MEG1NC=>
OPM-2 NWm0fpdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rXU|I1NzR6IHi= MWXFR|Uxez1z4pEJcm08KDR64pEJbC=> MkXmNlQxOzBzNUC=
RPMI-8226 MkPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;mV|I1NzR6IHi= NYL4elFGTUN3MIO9NU456oDLbl27JFQ56oDLaB?= NGjXfGszPDB|MEG1NC=>
U266 NEHHOHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\tNFI1NzR6IHi= NX3sPGdxTUN3MIO9NVDjiImwTUugOFjjiImq MlfPNlQxOzBzNUC=
CA46 MX3BdI9xfG:|aYOgRZN{[Xl? M3jzcFYhcA>? MVvpcoR2[2W|IHLseY51KGGyb4D0c5Nqew>? M1TqXlI{QTZ4MU[0
DG75 MX\BdI9xfG:|aYOgRZN{[Xl? NVOxRXZDPiCq M1jNOYlv\HWlZYOgco8h[XCxcITvd4l{ NV7m[291OjN7Nk[xOlQ>
Ramos MkezRZBweHSxc3nzJGF{e2G7 NFjU[Jg3KGh? MoHVbY5lfWOnczDlfJRmdnOrdnWgZZBweHSxc3nz MUKyN|k3PjF4NB?=
ST486 NHfhVFVCeG:ydH;zbZMhSXO|YYm= NWXQUnI2PiCq M3XZWYlv\HWlZYOg[Zh1\W6|aY\lJIFxd3C2b4Ppdy=> NFPnTXEzOzl4NkG2OC=>
HuT78 MXPBdI9xfG:|aYOgRZN{[Xl? MlroNU8yOC9zMECgcm0> M2\tTlQ5KGh? MVnpcoR2[2W|IHHwc5B1d3OrczDheEAyKG6P MViyN|U{Ojd|Mh?=
DpVp35 MnXkRZBweHSxc3nzJGF{e2G7 NHPPZZgyNzFyL{GwNEBvVQ>? MlTFOFghcA>? MVXpcoR2[2W|IHLseY51KGGyb4D0c5Nqew>? MWeyN|U{Ojd|Mh?=
DpVp50 NEPwNldCeG:ydH;zbZMhSXO|YYm= NFLyWVQyNzFyL{GwNEBvVQ>? M4rRSVQ5KGh? MlP2bY5lfWOnczDicJVvfCCjcH;weI9{cXN? NFztfWIzOzV|MkezNi=>
DpP75  M3L6e2Fxd3C2b4Ppd{BCe3OjeR?= NVfZSod3OS9zMD:xNFAhdk1? M3LpWFQ5KGh? NEG4[YZqdmS3Y3XzJIJtfW62IHHwc5B1d3Orcx?= MUWyN|U{Ojd|Mh?=
SKOV-3 NYPYSmhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\GbFHjiJN{MH7N NHz5N5M4OiCq NEXNZXpFVVOR NYrNfVVJemWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? NXXqN491OjNyMUCzOFg>
Brca1 WT NWC4OolZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{T1PVHjiJN{MH7N MmfYO|IhcA>? M1nnZWROW09? MmLYdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> MnnuNlMxOTB|NEi=
Brca1 Null MmHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPTeY11OeLCk{Kwcm0> MVq3NkBp NH3TZlRFVVOR M2LRZpJm\HWlZYOgZ4VtdCC4aXHibYxqfHliYXzvcoUh[W6mIHPvcYJqdmWmIIfpeIgh[2m|cHzheIlv M3LyOVI{ODFyM{S4
OVCAR-8  NXnqT2lqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXyydFF4OeLCk{Kwcm0> MX:3NkBp MXfEUXNQ MUjy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGGub37lJIFv\CClb33ibY5m\CC5aYToJINqe3CuYYTpci=> M1XjdFI{ODFyM{S4
NCI/ADR-RES NYHMSXdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fPVFHjiJN{MH7N M{HWRVczKGh? MWfEUXNQ MmL0doVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> MXGyN|AyODN2OB?=
HCT116 NF\MWVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn6zOUBvVS13MDFOwG0> MmPTNlQhcA>? MoXFSG1UVw>? M4C2WIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz MkP2NlI6OjR7NUi=
RKO NE\HbGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVi1JI5ONTVyIN88US=> MkTCNlQhcA>? Mnr1SG1UVw>? NHPaWXZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? MXSyNlkzPDl3OB?=
CO115 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfqZVlSPSCwTT21NEDPxE1? NFzidJIzPCCq NU\0UW1vTE2VTx?= MVTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> MkTrNlI6OjR7NUi=
HFS MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHzN5I2KG6P MUeyOE81QC95MjDo M2S0R4lvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWt[IVx\W6mZX70cJk> NHfGeZczOjFyNkK4Ni=>
LNCaP M3rqfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{e5blUhdk1? NVftbYp[OjRxNEivO|IhcA>? MnfYbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZT3k[ZBmdmSnboTsfS=> MXOyNlExPjJ6Mh?=
A549 M2LKdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;Xb4w2KG6P MWKyOE81QC95MjDo M1T1PYlvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWt[IVx\W6mZX70cJk> NFfH[Y4zOjFyNkK4Ni=>
697  Mn;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|Ux6oDLPfMAjVIvPcLibl2= MVGyNVU{QDJzNh?=
697-R MkfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|Ux6oDLPfMAjVgvPsLibl5CpC=> M2PU[VIyPTN6MkG2
HUT78 NXm5cHI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTxTWM2OD1zIH7N Mn7jNlEyQTh3NEW=
THJ-16T NHvrXmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4j2cFEhdk1? NYDnOVlvOjRiaB?= NF\ZbGVqdmirYnn0d{Bk\WyuIHfyc5d1cA>? MUKyNFgyODV4OB?=
HCT116 NH3pUopHfW6ldHnvckBCe3OjeR?= NH7GOWEzOCCwTR?= NF7zfGE5KGh? NXXNXG9vdW:mdXzheIV{KHS{YX7zZ5JqeHRibHX2[Yx{KG[xcjDoeY5lemWmczDv[kBo\W6nczDpckBmcXSqZYKg[Ilz\WO2aX;u MonuNlA4Ozl2NUS=
B104  M1vLdGZ2dmO2aX;uJGF{e2G7 M2ixRVIhdk1? NU\J[FRZOjRxNEivO|IhcA>? MmjKbY5kemWjc3XzJJRp\SC|dYLmZYNmKGW6cILld5Nqd25ib3[gR2QzOMLi Mmf3NlA3QDZ3MEW=
HL-60  M2H4XmN6fG:2b4jpZ4l1gSCDc4PhfS=> MX[xMVUxOCCwTR?= MWWyOEBp MoTXbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? NWHwZWpYOjB4MkSxOlM>
HP100 NV:1eG1yS3m2b4TvfIlkcXS7IFHzd4F6 MXWxMVUxOCCwTR?= NXHPRlNoOjRiaB?= NYjZRZY4cW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= MnPSNlA3OjRzNkO=
HL-60  MYjGeY5kfGmxbjDBd5NigQ>? M4LTRlExKG6P NXXZTlRjPC94L{G2JIg> MkD0bY5lfWOnczD0bIUh\2WwZYLheIlwdiCxZjDofYRzd2enbjDw[ZJwgGmmZTDmdo9uKDSq NWLsNY5YOjB4MkSxOlM>
HP100 MXrGeY5kfGmxbjDBd5NigQ>? NVnpbHZ7OTBibl2= NI[5VXo1NzZxMU[gbC=> NIjKc5NqdmS3Y3XzJJRp\SCpZX7ldoF1cW:wIH;mJIh6\HKxZ3XuJJBmem:6aXTlJIZzd21iNHi= MX6yNFYzPDF4Mx?=
HL-60  NY\JWm9CTnWwY4Tpc44hSXO|YYm= Mk[zNVAuPTByIH7N NF;wT2c1KGh? MXTk[YNz\WG|ZYOgeIhmKGirc4TvcoUh\GWjY3X0fYxie2ViKFjERWMqKGGldHn2bZR6yqB? NYTCZmwyOjB4MkSxOlM>
HP100 NYe5bVZQTnWwY4Tpc44hSXO|YYm= NUK1T5dVOTBvNUCwJI5O M1TCU|QhcA>? MWLk[YNz\WG|ZYOgeIhmKGirc4TvcoUh\GWjY3X0fYxie2ViKFjERWMqKGGldHn2bZR6yqB? NVjEXJpZOjB4MkSxOlM>
11z NILPN3VMcW6jc3WgRZN{[Xl? MmjNN{0yODBibl2= M36yU5Jm\HWlZYOgTGRCSyCnbor5cYF1cWNiYXP0bZZqfHliKFnDOVDDqD1iNj61JOKyKDBwNjDucY9tN0xr MnzSNlA3ODVzNES=
SKOV-3 MlXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnexOE85NzF4IH7N M3;JU|Q5KGh? NV;BeJkxcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? MUSyNFQxPDV4NB?=
OVCAR-3 NWn5eoc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3hNYs1NzhxMU[gcm0> MVe0PEBp NF;Fd|VqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? MVyyNFQxPDV4NB?=
HBL-2 M3L6VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TnU|IuOTBibl2= M1nmd|I1KGh? NXvmZYZjUUN3ME20MlMhdk1? NEfZeoIzODB4OEC4NC=>
Jeko-1 NVSzOZB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXmyMVUxKG6P NWfWR2NCOjRiaB?= MYfJR|UxRTFzIH7N NGnZWXEzODB4OEC4NC=>
Granta-519 NHrEe4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1K5dlUuPDBibl2= MlW4NlQhcA>? NF3FV4lKSzVyPUW4MlUhdk1? NIPM[mYzODB4OEC4NC=>
L1236 MUPDfZRwfG:6aXPpeJkhSXO|YYm= MUCxJI5ONTFyMDFOwG0> MYS0PEBp NGDlXnFGSzVyPUCuNFch|ryP Mm\nNVkzOzN2N{C=
L428 NUDqTWM6S3m2b4TvfIlkcXS7IFHzd4F6 MVKxJI5ONTFyMDFOwG0> MkfpOFghcA>? M1:3WWVEPTB;MD60N{DPxE1? NXLZO4d7OTl{M{O0O|A>
KM-H2 NY\pcmo4S3m2b4TvfIlkcXS7IFHzd4F6 NWLndpdkOSCwTT2xNFAh|ryP MYC0PEBp NFHZVWlGSzVyPUCuOVgh|ryP MVSxPVI{OzR5MB?=
L540Cy MomzR5l1d3SxeHnjbZR6KEG|c3H5 MmrwNUBvVS1zMECg{txO NVuzRo5PPDhiaB?= NIPsRVRGSzVyPUCuNVYh|ryP MWmxPVI{OzR5MB?=
G401 MnvWSpVv[3Srb36gRZN{[Xl? MnT5NVAhdk1? NFvzdFgzPC92OD:3NkBp MV7EUXNQ MnzjbY5kemWjc3XzJGNFU05zQzDlfJBz\XO|aX;u M3rjb|E6OjJzNUi2
STM91-01 MX3GeY5kfGmxbjDBd5NigQ>? MoHlNVAhdk1? NXLQbox6OjRxNEivO|IhcA>? NUP2WItzTE2VTx?= NFqwXmxqdmO{ZXHz[ZMhS0SNTkHDJIV5eHKnc4Ppc44> NIi0bIwyQTJ{MUW4Oi=>
SJSC  MoXrSpVv[3Srb36gRZN{[Xl? NWWzcmlrOTBibl2= NX7vSI5HOjRxNEivO|IhcA>? MnHLSG1UVw>? MWrpcoNz\WG|ZYOgR2RMVjGFIHX4dJJme3Orb36= M1TZW|E6OjJzNUi2
BT16  NYfQXXBkTnWwY4Tpc44hSXO|YYm= MXqxNEBvVQ>? NGjocGszPC92OD:3NkBp M3LQfWROW09? NEDBcFFqdmO{ZXHz[ZMhS0SNTkHDJIV5eHKnc4Ppc44> M2nxT|E6OjJzNUi2
NCI-H1299 MkPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnBVoIxUUN3ME20MlbDuTBwMjDu[{9udA>? NWHuUZFDOTlzN{m4PVA>
NCI-2882 M{jXW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\BVWlEPTB;MT62xtExNjB2IH7nM41t NXXuc3U3OTlzN{m4PVA>
HCC95 M3XTS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnPZlVKSzVyPUKuOeKyOC5yNTDu[{9udA>? M4S3OlE6OTd7OEmw
NCI-H23 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlv1TWM2OD1{LkpCtVAvOiCwZz;tcC=> MVKxPVE4QTh7MB?=
NCI-H157 MlWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTFwNtMxNE4xOiCwZz;tcC=> MoDMNVkyPzl6OUC=
NCI-H460 M1;yU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\STWlEPTB;Mj6xxtExNjB5IH7nM41t MUWxPVE4QTh7MB?=
NCI-H1975 NX;tNZVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPZTWM2OD1zLkRCtVAvODRibnevcYw> MU[xPVE4QTh7MB?=
NCI-H820 NYXnfmZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTJwNNMxNE4yKG6pL33s MWqxPVE4QTh7MB?=
NCI-H1650 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvVbYRKSzVyPUSuPeKyOC5|IH7nM41t MkXDNVkyPzl6OUC=
DTC1 NXHJdYVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXW5WlBmUUN3ME2wMlUyKG6P M1:zeFE5PTZ4MkS2
KAO MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXuXYVKSzVyPUCuPVEhdk1? MlLMNVg2PjZ{NE[=
SU-CCS-1 NH30d3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DDUmlEPTB;MD64PUBvVQ>? MmT1NVg2PjZ{NE[=
SYO-1 NYTj[mdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTBwNkegcm0> NXjCd3V1OTh3Nk[yOFY>
FUJI M{fZd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoD4TWM2OD1zLkOxJI5O M2HHe|E5PTZ4MkS2
SKNMC Mkm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTJTWM2OD1zLkG3JI5O M13OeVE5PTZ4MkS2
402-91 M4q1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTpTGFKSzVyPUGuNlYhdk1? Ml3aNVg2PjZ{NE[=
1765-92 MoHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2T3SGlEPTB;MT63O{BvVQ>? NIrFO5QyQDV4NkK0Oi=>
JN-DSRCT-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2i1ZmlEPTB;MT6yOUBvVQ>? NInYNGUyQDV4NkK0Oi=>
NMS-2PC NV3Sd|dxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwOEGgcm0> M1zjTVE5PTZ4MkS2
HL60 MnryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LtW2lEPTB;MT64OkBvVQ>? M2Xic|E5PTZ4MkS2
A549 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvYTWM2OD1|LkK0JI5O NFPSPXMyQDV4NkK0Oi=>
SW480 NETwZnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M332b2lEPTB;Mj62PUBvVQ>? M1jsS|E5PTZ4MkS2
MCF7 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTNwNUWgcm0> MVuxPFU3PjJ2Nh?=
PC-3 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrudGhKSzVyPUKuOVEhdk1? NFr3XlQyQDV4NkK0Oi=>
MMRU NH\jblRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorDTWM2OD1{LkW3JI5O NFHSW4UyQDV4NkK0Oi=>
Hs68 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LhSmlEPTB;PkGwJI5O NIH6RZEyQDV4NkK0Oi=>
hMSC-001F MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\iSYZuUUN3ME2+NVAhdk1? NVu4N4cxOTh3Nk[yOFY>

... Click to View More Cell Line Experimental Data

体内研究 与PBS处理的对照组相比,单独使用Erlotinib 和 Romidepsin分别可以对NCI-H1299细胞系的异种移植生长抑制到72% 和 43% ,但是并不具有明显的统计学意义。只有当两种药物联用的时候才会对其生长造成明显的抑制作用,此时生长被抑制到28% [1]。在免疫功能低下的小鼠中,Romidepsin 会抑制皮下NB 异种移植的生长,这种抑制作用具有剂量依赖的特性 。此外, 在NB病人的肿瘤组织中Romidepsin 会诱导某些基因的表达,如 p21 和p75 以及NTRK (TrkA) [2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

HDAC-inhibitory activity:

For the enzyme assay, 10 μL of [3H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [3H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
细胞实验:[3]
+ 展开
  • Cell lines: NCI-H1975, NCI-H157, NCI-2882, NCI-H460 和 HCC95 细胞系
  • Concentrations: 1 ng/mL
  • Incubation Time: 72 小时
  • Method: 使用MTS法分析药物敏感性。在96孔平板中每孔接种2×103个细胞(包括NCI-H1975, NCI-H157, NCI-2882, NCI-H460和HCC95) 。24小时后, 在存在或者缺少1 ng/mL Romidepsin的条件下将细胞与不同浓度 (0.01 µM - 250 µM) 的Erlotinib 37°C 孵育72 小时。 MTS 溶液加到每个孔中37°C孵育1小时。利用分光光度计测量490 nm 处的光密度值。每种药物浓度的实验都设置8个复孔并重复两次。基于细胞生存曲线的吸光度值计算药物的半抑制浓度 (IC50) 。
    (Only for Reference)
动物实验:[5]
+ 展开
  • Animal Models: 携带NCI-H1299 细胞的 BALB/c无胸腺裸小鼠
  • Formulation: 用PBS配制
  • Dosages: 1.2 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 10 mg/mL (18.49 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+30% PEG 300+5%Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 540.7
化学式

C24H36N4O6S2

CAS号 128517-07-7
稳定性 powder
in solvent
别名 FR 901228, NSC 630176

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03703375 Not yet recruiting Lymphoma T-Cell Celgene October 15 2018 Phase 3
NCT03547700 Recruiting Lymphoma T-Cell Peripheral Ryan Wilcox|University of Michigan Cancer Center|Takeda|Big Ten Cancer Research Consortium September 26 2018 Phase 1|Phase 2
NCT03355768 Not yet recruiting Lymphoma T-Cell Peripheral Jennifer Amengual|Columbia University September 2018 Phase 3
NCT03593018 Not yet recruiting Relapsed Angioimmunoblastic T-Cell Lymphoma|Refractory Angioimmunoblastic T-cell Lymphoma The Lymphoma Academic Research Organisation|Celgene September 2018 Phase 3
NCT03161223 Recruiting Lymphoma T-Cell Columbia University|University of Bologna|Samsung Medical Center|Celgene June 1 2018 Phase 1|Phase 2
NCT03432741 Recruiting Breast Adenocarcinoma|Recurrent Breast Carcinoma|Recurrent Hodgkin Lymphoma|Recurrent Mycosis Fungoides|Recurrent Non-Hodgkin Lymphoma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory Hodgkin Lymphoma|Refractory Mycosis Fungoides|Refractory Nodal Marginal Zone Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage IV Breast Cancer AJCC v6 and v7 Mayo Clinic|National Cancer Institute (NCI) March 27 2018 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品

Tags: 购买Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide)供应商 | 采购Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide)价格 | Romidepsin (FK228, Depsipeptide)生产 | 订购Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID